[Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma].
BACKGROUND
The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of the French Cancer Centres (FNCLCC), the 20 French Cancer Centres and specialists from French Public Universities, General Hospitals and Private Clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients. The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.


OBJECTIVE
To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the management of locally advanced non small cell lung carcinoma.


METHODS
Data were identified by searching Medline and the personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to independent reviewers and to the medical committees of the 20 French Cancer Centres.


RESULTS
The main recommendations are: 1) The management of the locally advanced non small cell lung carcinoma has two main goals: firstly to obtain local control of the disease (or to at least delay local progression in order to improve the survival or relapse free survival), and secondly to prevent the development of metastases. 2) There is a consensus that locally advanced non small cell lung carcinoma should be irradiated. External beam radiotherapy should be of optimal quality and delivered at a minimal dose of 60 Gy by standard fractionation. For patients with a poor life expectancy, this can be delivered as a split-course or hypofractionated scheme. 3) Treatment for patients with a performance status of 0-1 should consist of short duration induction chemotherapy (with a least two drugs one of which must be cisplatin), combined sequentially with conventional radiotherapy. 4) Surgery is contraindicated in extensive N3 disease. Combined radio-chemotherapy (adjuvant or neoadjuvant) is not indicated outside clinical trials. Surgery is justified in stage N2 disease as good local control can be achieved. T4-N0 disease should be treated surgically with curative intent.
Bardet
E
E
Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13.
Moro-Sibilot
D
D
Le Chevalier
T
T
Massard
G
G
Douillard
J Y
JY
Theobald
S
S
Astoul
P
P
Baldeyrou
P
P
Bazelly
B
B
Bréchot
J
J
Breton
J L
JL
Grivaux
P
P
Jacoulet
P
P
Khalil
A
A
Lemarie
E
E
Martinet
Y
Y
Milleron
B
B
Paesmans
M
M
Pujol
J L
JL
Quoix
A E
AE
Ranfaing
E
E
Rivière
A
A
Sancho-Garnier
H
H
Souquet
P J
PJ
Spaeth
D
D
Stcebner-Delbarre
A
A
Thiberville
L
L
Touboul
E
E
Vaylet
F
F
Vergnon
J M
JM
Westeel
V
V
Depierre
A
A
Lagrange
J L
JL
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic
D011838:Radiation-Sensitizing Agents; D002945:Cisplatin